-
6m 34s
-
2m 46sPart 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
10m 27sPart 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
3mPart 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
4m 27sPart 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
-
30m 45sPart 1 | Session 1 View from the Thoraxcenter: What's Hot at ACC.25?
-
39m 2sPart 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
-
17m 26sPart 2 | Session 1 ADVANCE-HTN: Lorundrostat in Patients with Uncontrolled Hypertension
-
11m 44sPart 2 | Session 2 STRIDE: Semaglutide for Functional Capacity in Patients with T2D and PAD
-
12m 9sPart 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
-
14m 1sPart 2 | Session 4 FRESH-UP: Liberal Intake Vs Fluid Restriction in Chronic Heart Failure
-
20m 59sPart 2 | Session 5 SOUL: Semaglutide in Patients with T2D
-
13m 47sPart 2 | Session 6 BHF PROTECT-TAVI: Cerebral Embolic Protection in TAVI
-
4m 15sPart 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
4m 3sPart 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
4m 14sPart 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
-
9m 39s
-
2m 54s
-
4m 58sPart 3 | Session 6 MIGHTy-Heart: Mobile Integrated Health in Heart Failure
-
7m 33s
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.
Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center). EKSTROM aimed to investigate the effect of colchicine on the progression of known coronary atherosclerosis in patients with stable CAD. The primary outcome measure was the rate of change in low attenuation plaque volume.
Low attenuation plaque was not significantly reduced, however, colcicine significantly reduced total plaque volume progression by 1.1% compared to placebo at one year. Colcicine treatment demonstrated trends towards regression of non-calcified plaque, fibrous and fibro-fatty plaque and significantly slowed dense calcium progression.
Interview Questions:
- What is the reasoning behind the EKSTROM trial?
- What was the study design and patient population?
- What were the key findings?
- Were there any surprising or unexpected results?
- What are the take-home messages for practice?
- What are the next steps?
Recorded on-site at ACC in Chicago, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Tom Green, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
More from this programme
Faculty Biographies
Matthew J Budoff
Professor of Medicine and Program Director and Director of Cardiac CT
Dr Matthew J Budoff, MD is a Professor of Medicine at the David Geffen School of Medicine at UCLA and the Director of Cardiac CT at Harbor-UCLA Medical Center in Torrance, CA.
Dr Budoff has conducted extensive research over the last 15 years using electron beam CT and multi-detector CT to identify those patients at high-risk for cardiac events, progression of coronary calcium, and non-invasive CT angiography.
He is the Vice President of the Society of Atherosclerosis Imaging (SAI) and a founding Board Member of the Society of Cardiovascular CT (SCCT). Previously, he served as chair of the ACC/AHA Competency document for cardiac CT and MR; the COCATS 2–CT Section (ACC training for fellows); as well as the AHA Scientific Statement on Cardiac CT.
Dr Budoff is an author of the updated Guidelines for Use of CT for Calcium Assessment and the competency guidelines for peripheral CT and MRI. Dr Budoff is a cum laude graduate of the…
Comments